S&P 500   5,068.20 (-0.03%)
DOW   38,921.87 (-0.38%)
QQQ   437.11 (+0.13%)
AAPL   180.96 (-0.11%)
MSFT   406.05 (-0.37%)
META   484.37 (+0.55%)
GOOGL   138.15 (+0.42%)
AMZN   174.02 (-0.41%)
TSLA   201.64 (+1.12%)
NVDA   786.50 (-0.56%)
NIO   5.75 (+1.77%)
AMD   177.01 (+0.57%)
BABA   77.60 (+1.42%)
T   16.64 (+0.24%)
F   12.01 (+0.50%)
MU   90.87 (+1.58%)
CGC   3.51 (+1.15%)
GE   153.68 (-0.70%)
DIS   108.29 (+0.57%)
AMC   4.64 (+4.27%)
PFE   26.98 (-0.74%)
PYPL   59.61 (+0.47%)
XOM   104.20 (-0.05%)
S&P 500   5,068.20 (-0.03%)
DOW   38,921.87 (-0.38%)
QQQ   437.11 (+0.13%)
AAPL   180.96 (-0.11%)
MSFT   406.05 (-0.37%)
META   484.37 (+0.55%)
GOOGL   138.15 (+0.42%)
AMZN   174.02 (-0.41%)
TSLA   201.64 (+1.12%)
NVDA   786.50 (-0.56%)
NIO   5.75 (+1.77%)
AMD   177.01 (+0.57%)
BABA   77.60 (+1.42%)
T   16.64 (+0.24%)
F   12.01 (+0.50%)
MU   90.87 (+1.58%)
CGC   3.51 (+1.15%)
GE   153.68 (-0.70%)
DIS   108.29 (+0.57%)
AMC   4.64 (+4.27%)
PFE   26.98 (-0.74%)
PYPL   59.61 (+0.47%)
XOM   104.20 (-0.05%)
S&P 500   5,068.20 (-0.03%)
DOW   38,921.87 (-0.38%)
QQQ   437.11 (+0.13%)
AAPL   180.96 (-0.11%)
MSFT   406.05 (-0.37%)
META   484.37 (+0.55%)
GOOGL   138.15 (+0.42%)
AMZN   174.02 (-0.41%)
TSLA   201.64 (+1.12%)
NVDA   786.50 (-0.56%)
NIO   5.75 (+1.77%)
AMD   177.01 (+0.57%)
BABA   77.60 (+1.42%)
T   16.64 (+0.24%)
F   12.01 (+0.50%)
MU   90.87 (+1.58%)
CGC   3.51 (+1.15%)
GE   153.68 (-0.70%)
DIS   108.29 (+0.57%)
AMC   4.64 (+4.27%)
PFE   26.98 (-0.74%)
PYPL   59.61 (+0.47%)
XOM   104.20 (-0.05%)
S&P 500   5,068.20 (-0.03%)
DOW   38,921.87 (-0.38%)
QQQ   437.11 (+0.13%)
AAPL   180.96 (-0.11%)
MSFT   406.05 (-0.37%)
META   484.37 (+0.55%)
GOOGL   138.15 (+0.42%)
AMZN   174.02 (-0.41%)
TSLA   201.64 (+1.12%)
NVDA   786.50 (-0.56%)
NIO   5.75 (+1.77%)
AMD   177.01 (+0.57%)
BABA   77.60 (+1.42%)
T   16.64 (+0.24%)
F   12.01 (+0.50%)
MU   90.87 (+1.58%)
CGC   3.51 (+1.15%)
GE   153.68 (-0.70%)
DIS   108.29 (+0.57%)
AMC   4.64 (+4.27%)
PFE   26.98 (-0.74%)
PYPL   59.61 (+0.47%)
XOM   104.20 (-0.05%)
NASDAQ:CASI

CASI Pharmaceuticals (CASI) Stock Price, News & Analysis

$5.34
-0.10 (-1.84%)
(As of 10:46 AM ET)
Today's Range
$5.30
$5.46
50-Day Range
$4.77
$7.85
52-Week Range
$1.60
$8.48
Volume
2,355 shs
Average Volume
32,167 shs
Market Capitalization
$71.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

CASI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
120.6% Upside
$12.00 Price Target
Short Interest
Healthy
0.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.50
Upright™ Environmental Score
News Sentiment
0.15mentions of CASI Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

190th out of 942 stocks

Biological Products, Except Diagnostic Industry

25th out of 152 stocks


CASI stock logo

About CASI Pharmaceuticals Stock (NASDAQ:CASI)

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Stock Price History

CASI Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CASI Pharmaceuticals Inc CASI
CASI Pharmaceuticals Posts Narrower Loss In Q3
CASI Pharmaceuticals, Inc. Q2 Loss Widens
See More Headlines
Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
2/26/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CASI
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+120.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,010,000.00
Pretax Margin
-87.15%

Debt

Sales & Book Value

Annual Sales
$43.11 million
Book Value
$3.28 per share

Miscellaneous

Free Float
10,492,000
Market Cap
$72.46 million
Optionable
Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Wei-Wu He Ph.D. (Age 59)
    Chairman & CEO
    Comp: $565.36k
  • Dr. Wei Zhang Ph.D. (Age 64)
    President
    Comp: $1.13M
  • Dr. Alexander A. Zukiwski M.D. (Age 67)
    Executive VP & Chief Medical Officer
    Comp: $514.79k
  • Ms. Kun Qian (Age 42)
    VP & Global Controller
  • Ms. Chunhua Wang (Age 52)
    Chief Operating Officer
  • Ms. Wei Gao (Age 43)
    General Counsel
  • Dr. James E. Goldschmidt Ph.D.
    Chief Business Development Officer
  • Mr. Hai Huang
    Global Chief Commercial Officer
  • Ms. Amanda Cui
    VP & Global Controller














CASI Stock Analysis - Frequently Asked Questions

Should I buy or sell CASI Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI shares.
View CASI analyst ratings
or view top-rated stocks.

What is CASI Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 12 month target prices for CASI Pharmaceuticals' shares. Their CASI share price targets range from $12.00 to $12.00. On average, they predict the company's share price to reach $12.00 in the next year. This suggests a possible upside of 120.6% from the stock's current price.
View analysts price targets for CASI
or view top-rated stocks among Wall Street analysts.

How have CASI shares performed in 2024?

CASI Pharmaceuticals' stock was trading at $7.16 on January 1st, 2024. Since then, CASI stock has decreased by 24.0% and is now trading at $5.44.
View the best growth stocks for 2024 here
.

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 52,700 shares, an increase of 10.0% from the January 15th total of 47,900 shares. Based on an average daily trading volume, of 51,200 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.9% of the shares of the company are sold short.
View CASI Pharmaceuticals' Short Interest
.

When is CASI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our CASI earnings forecast
.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.27. The biotechnology company earned $9.82 million during the quarter, compared to the consensus estimate of $10.09 million. CASI Pharmaceuticals had a negative net margin of 95.24% and a negative trailing twelve-month return on equity of 110.90%.

When did CASI Pharmaceuticals' stock split?

CASI Pharmaceuticals shares reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James Huang and Wei-Wu He.
View institutional ownership trends
.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CASI) was last updated on 2/27/2024 by MarketBeat.com Staff